Chicago, ILNCT06355310Now EnrollingIRB Ready

Non-Alcoholic Fatty Liver Disease Clinical Trial in Chicago, IL

Access cutting-edge non-alcoholic fatty liver disease treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Justin Ryder

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access non-alcoholic fatty liver disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-alcoholic fatty liver disease treatment provided free

Apply for This Chicago Location

Check if you qualify for this non-alcoholic fatty liver disease clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Non-Alcoholic Fatty Liver Disease Study in Chicago

This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

Sponsor: Justin Ryder

Who Can Participate

Inclusion Criteria

For clinical referral to screening visit:
BMI \>30 kg/m2 or \>95th BMI-Percentile
Weight Range of 75kg to 150kg
Age 16 to \<21 at baseline
Elevated alanine aminotransferase (ALT) more than twice the upper limit of normal by gender (≥ 44 U/L for girls, ≥ 50 U/L for boys)63 within 3 months prior to screening (used for historic ALT value) OR diagnosis of NAFLD from ultrasound, MRI, or participants with biopsy-proven NASH within 12 months of screening.
History of lifestyle modification to treat obesity or NAFLD.
Tanner stage \>2
Normal fasting glucose (fasting blood glucose \<100 mg/dL) To be obtained at screening visit:
Confirmation of obesity;
Tanner stage 2,3,4 or 5;
Normal fasting glucose tolerance (fasting blood glucose \<100 mg/dL);
If Screening ALT is used as inclusion criteria (if \> 2x historic ALT value (historical value obtained clinically within 12 months of screening visit), repeated after 4 weeks \[unable to randomize until completed\]. If the repeat ALT is more than 50% increased or decreased over the screening ALT, a third ALT should be obtained. If a third ALT is not within 50% of the previous value, then the subject is ineligible but may be rescreened at a later date. If ALT is not used:
An ultrasound will be done to diagnose NAFLD if the diagnosis has not previously been made by ultrasound, MRI or biopsy.
A MRI-derived HFF ≥ 5.5%
Willingness to adhere to lifestyle considerations throughout the study

Exclusion Criteria

ALT \> 250U/L at screening
History of significant alcohol intake or current use
Impaired fasting glucose (\>100 mg/dL)
Diabetes (type 1 or 2)
Current or recent (\<6 months prior to enrollment) use of weight loss medication(s)
Vitamin E supplementation or use of metformin -washout period 30 days
Previous bariatric surgery
Prior use of empagliflozin
Lower limb infection/ulceration within 3 months of screening
Metal or magnetic implants, devices or objects inside of or on the body, which are not MRI compatible
Structural and functional urogenital abnormalities, that predispose for urogenital infections
Recent initiation (\<3 months prior to enrollment) of anti-hypertensive or lipid medication(s)
Major psychiatric disorder
Known hypothalamic or pituitary dysfunction
Current pregnancy or plans to become pregnant
Females unwilling to be tested for pregnancy
Females who are sexually active and not protects by an effective method of birth control (e.g. UID or medication or patch) -can re-screen 30 days after getting on birth control
Tobacco use
Significant liver dysfunction (levels \>5 times the upper limit of normal (ULN)):
ALT (ULN = 50 U/L)
AST (ULN = 48 U/L)
GGT (ULN = 48 U/L)
ALP (ULN = 115 U/L)
Platelets \< 150,000 cells/mm3
Total bilirubin \> 1.3 mg/dL
Albumin \<3.2 g/dL
Gilbert's Syndrome
Any known causes of liver disease (except NAFLD and NASH)
Significant renal dysfunction (estimated glomerular filtration rate \[eGFR\] \< 80 mL/min/1.73 m2),
Diagnosed monogenic obesity
History of cancer
Untreated thyroid disorder
History of decompensation events (ascites, variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma)
Current or recent (\<6 months prior to enrollment) use of medication(s) associated with weight gain (e.g. atypical anti-psychotics).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT06355310) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Alcoholic Fatty Liver Disease Treatment Options in Chicago, IL

If you're searching for non-alcoholic fatty liver disease treatment options in Chicago, IL, this clinical trial (NCT06355310) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-alcoholic fatty liver disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-alcoholic fatty liver disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Chicago, IL

See all ankylosing spondylitis clinical trials recruiting in Chicago — not just this study.

Browse Ankylosing Spondylitis Trials in Chicago →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsNASH TrialsLiver Disease TrialsInterstitial Cystitis TrialsNon-Alcoholic Fatty Liver Disease TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL